Amneal Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Chirag K. Patel
- Full Time Employees
- 8,700
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 400 Crossing Boulevard Bridgewater NJ United States of America 08807
- IPO Date
- May 7, 2018
- CIK
- 0001723128
- Website
- amneal.com
- Similar Companies
- Business
- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a global biopharmaceutical enterprise focused on enhancing health through the creation, production, and distribution of an extensive array of generic and specialized pharmaceutical products. Operating primarily within the United States, the company serves a broad spectrum of therapeutic areas and patient needs. The company's operations are strategically divided into three main segments: Affordable Medicines (previously Generics), Specialty, and AvKARE. The Affordable Medicines segment is dedicated to developing, manufacturing, and commercializing a diverse portfolio of generic drugs, including complex oral solids, sterile injectables, ophthalmics, liquids, topicals, biosimilars, and inhalation products. Amneal has been actively expanding its injectables portfolio, launching new products to address critical drug shortages, particularly in areas like oncology. This segment also includes the company's retail generics and international revenues. The Specialty segment concentrates on branded pharmaceutical products, primarily targeting central nervous system disorders, such as Parkinson's disease and migraine, and endocrine disorders like hypothyroidism. Key products in this division include Rytary for Parkinson's disease, Unithroid for hypothyroidism, and more recently launched products like Brekiya, an autoinjector for acute migraine and cluster headaches, and CREXONT for Parkinson's disease. Amneal aims to expand this portfolio through internal development, acquisitions, and strategic partnerships. The AvKARE segment functions as a distributor of pharmaceuticals, medical, and surgical products and services. It predominantly serves governmental agencies, including the Department of Defense and the Department of Veterans Affairs. AvKARE also engages in the wholesale distribution and packaging of bottle and unit-dose pharmaceuticals under its own labels, supplying both retail and institutional customers. Amneal acquired a majority interest in AvKARE in 2019 to bolster its presence in the federal healthcare market. Amneal distributes its products through a robust network that includes wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company maintains a global footprint with operations in the United States, India, Ireland, and other international markets. Founded in 2002 by Chirag and Chintu Patel, Amneal Pharmaceuticals, Inc. is headquartered in Bridgewater, New Jersey. The company became publicly traded in 2018 through a merger and continues to invest in research and development to bring new and complex medicines to market.
Company News
5 Defensive Stocks to Buy as Consumer Confidence Hits 7-Month Low
4 Healthcare Stocks to Safeguard Your Portfolio as Fed Plans Rate Hike
STOCK ALERT: Kaskela Law Announces Shareholder Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages Current AMRX Stockholders to Contact the Firm
5 Top-Ranked High-Efficiency Stocks Poised for Stronger Returns
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?
Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader
Amneal (AMRX) Upgraded to Buy: What Does It Mean for the Stock?
Arkadios Wealth Advisors Takes Position in Amneal Pharmaceuticals, Inc. $AMRX
AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised
Amneal Pharmaceuticals, Inc. (AMRX) Q2 2026 Earnings Call Transcript
Compared to Estimates, Amneal (AMRX) Q2 Earnings: A Look at Key Metrics
Amneal Pharmaceuticals Q2 Earnings Call Highlights
Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Surpass Estimates
Amneal Reports Second Quarter 2026 Financial Results
Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm
Here's Why Amneal Pharmaceuticals (AMRX) is a Strong Growth Stock
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations